The tumor-suppressive outcome is driven by combined molecular changes: downregulation of SPARCL1 and PSME3, coupled with upregulation of the NF-κB inhibitor NFKBIA and downregulation of CD44 and CCL15, collectively promotes apoptosis while suppressing proliferation, migration, and angiogenesis. Here, SPARCL1 is linked to neoplasm.